MUC1 and MGAM Detection in Urinary Extracellular Vesicles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting early stages of kidney dysfunction in children are inadequate, as they often overlook irreversible nephron loss, and a reliable biomarker using urinary extracellular vesicles (uEVs) has not been confirmed.
Innovation Solution
A method involving the measurement of MUC1 and/or MGAM expression in phosphatidylserine-positive urinary extracellular vesicles, with optional CD9 measurement, to detect kidney dysfunction and determine renal prognosis by calculating the MGAM/MUC1 ratio, using a detection kit containing anti-MUC1 and/or anti-MGAM antibodies, and a substance with affinity for uEVs like Tim4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional blood tests and urine tests are used for kidney dysfunction detection, then the testing method is simple and non-invasive, but the early stages of nephron loss may be overlooked and detection accuracy is insufficient
Solution Approach 1:
The invention extracts and isolates specific biomarkers (MUC1 and MGAM proteins) from urinary extracellular vesicles to create a targeted detection method. By focusing on these specific proteins within uEVs rather than general urine components, the method achieves higher detection accuracy for early kidney dysfunction while maintaining relative simplicity through specialized assay techniques
Solution Approach 2:
The invention uses urinary extracellular vesicles as an intermediary carrier that protects and delivers the biomarkers (MUC1 and MGAM proteins) from the kidney tissue to the urine sample. These uEVs serve as a stable medium that preserves the integrity of the biomarkers, enabling accurate detection without requiring direct tissue sampling or complex processing
2Reliability
If a biomarker using urinary extracellular vesicles is developed, then detection accuracy and non-invasive capability are improved, but the method complexity and lack of confirmed reliable biomarker increase
Solution Approach 1:
The invention segments the detection process into distinct stages: first isolating urinary extracellular vesicles from urine samples, then specifically detecting the MUC1 and MGAM proteins within those vesicles. This segmentation allows each step to be optimized independently, making the overall complex process more manageable and reliable
Solution Approach 2:
The invention changes the detection parameters by focusing on specific protein markers (MUC1 and MGAM) within a specific carrier (uEVs) rather than measuring general urine composition. This parameter change enables more reliable detection of early kidney dysfunction by targeting molecules that are specifically altered in kidney disease states
3Loss of time
If early diagnosis of kidney dysfunction is achieved through novel biomarkers, then patient outcomes and prognosis determination are improved, but the complexity of identification and validation increases
Solution Approach 1:
The invention performs preliminary action by establishing a validated detection system for MUC1 and MGAM proteins in uEVs that can be applied immediately to clinical samples. The biomarkers and detection methodology have been pre-validated through research, allowing rapid deployment for early diagnosis without requiring additional complex validation steps for each new patient
Solution Approach 2:
The invention replaces complex mechanical tissue biopsy procedures with a simpler urine-based detection system. By substituting invasive mechanical sampling with non-invasive urine collection and biochemical detection of MUC1/MGAM in uEVs, the system achieves early diagnosis capability without the complexity and risks of tissue sampling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and non-invasive diagnosis of kidney dysfunction and prognosis, improving detection capabilities beyond existing methods by utilizing specific protein markers in uEVs.
Implementation Method 1
a detection kit for a kidney dysfunction diagnostic marker, the kit containing an anti-MUC1 antibody and/or an anti-MGAM antibody
Implementation Method 2
the urinary extracellular vesicles are phosphatidylserine-positive
Data Source
AI summary
A method for detecting a kidney dysfunction diagnostic marker, the method including measurement of an expression amount of MUC1 and/or MGAM in urinary extracellular vesicles derived from a subject.